BRIEF published on 07/15/2024 at 09:35, 1 year 4 months ago Amolyt Pharma, a Portfolio Company of Andera Partners, Acquired by AstraZeneca Acquisition Biopharmaceuticals AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 07/15/2024 at 09:30, 1 year 4 months ago Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca Andera Partners' portfolio company Amolyt Pharma has been acquired by AstraZeneca for $1.05 billion, enhancing AstraZeneca's Rare Disease late-stage pipeline and bone metabolism franchise Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Andera Partners
BRIEF published on 07/09/2024 at 08:15, 1 year 4 months ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 1 year 4 months ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 1 year 8 months ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 1 year 8 months ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 1 year 8 months ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 1 year 8 months ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
PRESS RELEASE published on 05/15/2023 at 09:00, 2 years 6 months ago Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
PRESS RELEASE published on 05/10/2023 at 09:00, 2 years 6 months ago Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
Published on 12/05/2025 at 02:35, 5 hours 6 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 41 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 36 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 41 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 41 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 11 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 50 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 16 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 26 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 41 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 56 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 57 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
